CELEX: 62018CA0673
Language: en
Date: 2020-07-09 00:00:00
Title: Case C-673/18: Judgment of the Court (Grand Chamber) of 9 July 2020 (request for a preliminary ruling from the Cour d’appel de Paris — France) — Santen SAS v Directeur général de l’Institut national de la propriété industrielle (Reference for a preliminary ruling — Medicinal product for human use — Supplementary protection certificate for medicinal products — Regulation (EC) No 469/2009 — Article 3(d) — Conditions for the grant of a certificate — Obtaining the first authorisation to place the product on the market as a medicinal product — Authorisation to place on the market a new therapeutic application of a known active ingredient)

31.8.2020   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 287/3
            
         
      Judgment of the Court (Grand Chamber) of 9 July 2020 (request for a preliminary ruling from the Cour d’appel de Paris — France) — Santen SAS v Directeur général de l’Institut national de la propriété industrielle
      (Case C-673/18) (1)
      
      (Reference for a preliminary ruling - Medicinal product for human use - Supplementary protection certificate for medicinal products - Regulation (EC) No 469/2009 - Article 3(d) - Conditions for the grant of a certificate - Obtaining the first authorisation to place the product on the market as a medicinal product - Authorisation to place on the market a new therapeutic application of a known active ingredient)
      (2020/C 287/04)
      Language of the case: French
      
         Referring court
      
      Cour d’appel de Paris
      
         Parties to the main proceedings
      
      
         Applicant: Santen SAS
      
         Defendant: Directeur général de l’Institut national de la propriété industrielle
      
         Operative part of the judgment
      
      Article 3(d) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products must be interpreted as meaning that a marketing authorisation cannot be considered to be the first marketing authorisation, for the purpose of that provision, where it covers a new therapeutic application of an active ingredient, or of a combination of active ingredients, and that active ingredient or combination has already been the subject of a marketing authorisation for a different therapeutic application.
      
         (1)  OJ C 25, 21.1.2019.